New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - mitomycin 10mg - powder for injection - 10 mg - active: mitomycin 10mg excipient: mannitol - mitomycin is used in palliative tumour therapy. mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of: · advanced metastatic gastric carcinoma · advanced and/or metastatic breast cancer furthermore mitomycin is administered intravenously in combined chemotherapy in the case of: · non-small cell bronchial carcinoma · advanced pancreatic carcinoma intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - mitomycin 2mg - powder for injection - 2 mg - active: mitomycin 2mg excipient: mannitol - mitomycin is used in palliative tumour therapy. mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of: · advanced metastatic gastric carcinoma · advanced and/or metastatic breast cancer furthermore mitomycin is administered intravenously in combined chemotherapy in the case of: · non-small cell bronchial carcinoma · advanced pancreatic carcinoma intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - mitomycin 20mg - powder for injection - 20 mg - active: mitomycin 20mg excipient: mannitol - mitomycin is used in palliative tumour therapy. mitomycin is administered intravenously as monochemotherapy or in combined cytostatic chemotherapy in the case of: · advanced metastatic gastric carcinoma · advanced and/or metastatic breast cancer furthermore mitomycin is administered intravenously in combined chemotherapy in the case of: · non-small cell bronchial carcinoma · advanced pancreatic carcinoma intravesical administration for relapse prevention in superficial urinary bladder carcinoma after transurethral resection.

Australia - English - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - mitomycin -

Malta - English - Medicines Authority

ej busuttil ltd busuttil buildings, triq l-ghadam, central business district zone 1, birkirkara, cbd 1060, malta - mitomycin - powder for solution for injection/infusion - mitomycin 20 mg - antineoplastic agents

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - mitomycin - powder for solution for injection - mitomycin 40 mg - antineoplastic agents

Malta - English - Medicines Authority

p & d pharmaceuticals limited 38 woolmer way, bordon hampshire gu35 9qf, united kingdom - mitomycin - powder for solution for injection - mitomycin 2 mg - antineoplastic agents

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mitomycin - powder for solution for injection - mitomycin 40 milligram(s) - antineoplastic agents

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - mitomycin - powder for solution for injection - mitomycin 40 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

echo therapeutics pty ltd - mitomycin, quantity: 20 mg - injection, powder for - excipient ingredients: nitrogen; mannitol; hydrochloric acid; sodium hydroxide - mitomycin is indicated in the palliative treatment of carcinoma of the stomach, pancreas, colon, lung (non-small cell), breast, cervix, head and neck, liver and bladder.